| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12504345 | IVR | 50 mg/kg/day | - | No significant effects observed | - |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects locomotor activity | Neurological endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| PMID:16280211 | IVTH | 0 | - | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:22531466 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:24563381 | IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:30120946 | IVR | 0.05 mg/L | 0.05 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/L | - | No significant effects observed | - | |
| PMID:30871434 | IVR | 5 mg/kg/day | - | No significant effects observed | - |
| IVR | 25 mg/kg/day | - | No significant effects observed | - | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| PMID:31388671 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:31424294 | IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 - 5 mg/kg | 0.5 - 5 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 - 5 mg/kg | 0.5 - 5 mg/kg | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations | |
| PMID:31514588 | IVR | 0.025 - 0.05 mg/L | 0.025 - 0.05 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/L | 0.05 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 - 0.05 mg/L | 0.025 - 0.05 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| PMID:31896186 | IVR | 12.5 mg/kg | 12.5 mg/kg | Alters sperm function | Reproductive endocrine-mediated perturbations |
| IVR | 37.5 mg/kg | 37.5 mg/kg | Oxidative stress in sperm | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Oxidative stress in sperm | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 37.5 mg/kg | 37.5 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 37.5 mg/kg | 37.5 mg/kg | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 37.5 mg/kg | 37.5 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 37.5 mg/kg | 37.5 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| PMID:32387340 | IVTH | 0.000025 M | 0.000025 M | Affects estrogen signaling | Reproductive endocrine-mediated perturbations |
| PMID:32508751 | IVTH | 0.000025 M | 0.00001487 M | Affects calcium signaling in sperm | Reproductive endocrine-mediated perturbations |
| PMID:32927158 | IVTH | 0.000000001 - 0.0001 M | 0.000000001 - 0.0001 M | Induce neuronal apoptosis | Neurological endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.0001 M | 0.0000001 - 0.0001 M | Induce apoptosis in adipose tissue | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000001 - 0.0001 M | 0.000000001 - 0.0001 M | Increased oxidative stress in neurons | Neurological endocrine-mediated perturbations | |
| PMID:33753083 | IVTH | 0.00000000156 - 0.000000025 M | 0.00000000156 - 0.000000025 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000025 M | 0.000000025 M | Increase in estradiol/testosterone ratio | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000000625 - 0.000000025 M | 0.00000000625 - 0.000000025 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:34186270 | IVTH | 0.000001 M | 0.000001 M | Decreased adiponectin levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Increased leptin levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00005 M | 0.00000001 - 0.00005 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:35101577 | IVTH | 0.00003 M | 0.00003 M | Altered adipogenesis | Metabolic endocrine-mediated perturbations |
| PMID:37164221 | IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects testicular development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects penis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:37939739 | IVTH | 0.0001 M | 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:38276253 | IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000005 - 0.0000001 M | 0.00000005 - 0.0000001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000005 - 0.0001 M | 0.0000005 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0001 M | 0.00001 - 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.0001 M | 0.0000001 - 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:39474496 | IVR | 0.3 mg/kg | 0.3 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Cancer phenotype | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.